Neovacs, BioSense Ink Accord to Develop Lupus Vaccine in China
Neovacs and BioSense Global will jointly develop an interferon alpha (IFNα) vaccine to treat lupus and dermatomyositis in China. News of the commercial licensing agreement, worth up to €65 million, comes just days after Chinese authorities issued a patent for Neovacs’ IFNα vaccine (IFNα Kinoid) for diseases characterized by over-expression of the cytokine…